| Sarcoidosis-associated pulmonary hypertension: assessment and management. | |
| | |
MedLine Citation:
|
PMID: 20665399 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Pulmonary hypertension (PH) is a recognized complication of sarcoidosis, with increased morbidity and poor prognosis. Sarcoidosis-associated pulmonary hypertension (SAPH) is typically seen in advanced cases, with pulmonary fibrosis, destruction and obliteration of the pulmonary vasculature, and chronic hypoxemia. PH can, however, occur in the absence of pulmonary fibrosis, suggesting alternative pathophysiological mechanisms. Diverse processes may coexist in the pathogenesis of SAPH, and there is an overlap with mechanisms of pulmonary arterial hypertension (PAH). This has encouraged the study of PAH-specific therapeutic agents in the treatment of SAPH. In small series, prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors have been shown to improve hemodynamics, functional status, and outcomes. This article reviews the most recent data available in the epidemiology, pathophysiology, diagnosis, and treatment of SAPH. |
| | |
Authors:
|
Veronica Palmero; Roxana Sulica |
Related Documents
:
|
16292989 - Sitaxsentan: a novel endothelin-a receptor antagonist for pulmonary arterial hypertension. 15891429 - Idiopathic pulmonary arterial hypertension in children. 2488759 - Effect of prolonged inhibition of angiotensin converting enzyme by captopril on some he... 984069 - Pulmonary hypertension and foreign body granulomas in intravenous drug abusers. documen... 17365199 - Idiopathic pulmonary arterial hypertension misdiagnosed as asthma. 20956119 - Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options. 16129789 - Pergolide is an inhibitor of voltage-gated potassium channels, including kv1.5, and cau... 18395629 - Transcatheter percutaneous and transapical aortic valve replacement. 22245279 - Headache after substance abuse: a diagnostic dilemma. |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-07-27 |
Journal Detail:
|
Title: Seminars in respiratory and critical care medicine Volume: 31 ISSN: 1098-9048 ISO Abbreviation: Semin Respir Crit Care Med Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-28 Completed Date: 2010-11-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9431858 Medline TA: Semin Respir Crit Care Med Country: United States |
Other Details:
|
Languages: eng Pagination: 494-500 Citation Subset: IM |
Copyright Information:
|
Copyright Thieme Medical Publishers. |
Affiliation:
|
Division of Pulmonary and Critical Care Medicine, Beth Israel Medical Center, New York, NY 10003, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cyclic Nucleotide Phosphodiesterases, Type 5
/
antagonists & inhibitors Humans Hypertension, Pulmonary / diagnosis, drug therapy*, etiology Phosphodiesterase Inhibitors / therapeutic use Prognosis Prostaglandins I / therapeutic use Pulmonary Fibrosis / diagnosis, drug therapy, etiology Receptors, Endothelin / antagonists & inhibitors Sarcoidosis / complications*, diagnosis, drug therapy |
| Chemical | |
Reg. No./Substance:
|
0/Phosphodiesterase Inhibitors; 0/Prostaglandins I; 0/Receptors, Endothelin; EC 3.1.4.35/Cyclic Nucleotide Phosphodiesterases, Type 5 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Quality of Life in Sarcoidosis: Assessment and Management.
Next Document: Treatment of Sarcoidosis.